Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia
Data Presented at the 55th American Society of Hematology Annual Meeting NEW ORLEANS–(BUSINESS WIRE)–Dec. 7, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed or refractory hematologic malignancies. The data show that […]